We are international
Donate
TEXT SIZE   


Myeloma Minute
August 27, 2015
08.27.15
August 27, 2015
Share the Minute Facebook Tweet!
Clinical Trials
Donate to the IMF
   

 
This week's question: What is the latest news about the Black Swan Research Initiative?


Multiple Myeloma Bone Study

New Selinexor STORM Clinical Trials: Learn How To Participate

New Ixazomib Clinical Trials: Learn How to Participate

Join the conversation about myeloma on the Smart Patients Message Board

Upcoming Events

Saturday, August 29, 2015
3rd Annual Race to Beat Myeloma Oceanport, New Jersey

Saturday, September 19, 2015
Regional Community Workshop (RCW)
Richmond, Virginia

September 23-26, 2015
XV International Myeloma Workshop
Rome, Italy


Saturday, October 10, 2015
 9th Annual Comedy Celebration

Los Angeles, California


November 21, 2015

Regional Community Workshop (RCW)
Chicago, Illinois

 


Watch the IMF Mambo for Myeloma & Support This Challenge

    

x

Daratumumab Shows 36% Efficacy Rate in Treating Relapsed and Refractory Multiple Myeloma in Study

A study published in the New England Journal of Medicine today announced that daratumumab, a monoclonal antibody, has shown favorable treatment results in phase 1 and phase 2 trials for patients with relapsed or refractory myeloma. According to the study and a press release issued by daratumumab manufacturers Genmab and Johnson & Johnson, the data showed a 36% response rate in the group treated in phase two of the study and furthermore, 65% of those patients had not experienced disease progression in the 12 months after the start of treatment. Read Dr. Durie’s commentary on the study, HERE.

x

2 Top Medical Journals Weigh in on Potential Danger of Toxic Chemicals


 

Reports in two highly respected medical journals—the Lancet and the New England Journal of Medicine—agree that weed killers used with genetically modified crops (commonly known as GMOs), such as corn and soybeans, cause cancer. In his blog this week, IMF Chairman Dr. Brian Durie writes that in light of the evidence, it’s vitally important for consumers to know what’s in their food. To read, click

HERE.

 

x

Expanded Access Program for Elotuzumab

 

An Expanded Access Program (EAP) for elotuzumab with lenalidomide (Revlimid®) and dexamethasone is now open for myeloma patients with relapsed or refractory multiple myeloma. Elotuzumab is the first monoclonal antibody developed to treat multiple myeloma. Clinical trials have provided insights that elotuzumab works more effectively in combination with the immunomodulatory agent Revlimid and the steroid dexamethasone than alone. To learn more about the elotuzumab EAP, read the IMF’s Clinical Trial Fact Sheet, HERE.

x

Watch the IMF Patient & Family Seminar Live Stream Replay on IMF TV


 

For those who weren’t able to attend the IMF Patient & Family Seminar in Los Angeles last weekend, there is a live stream replay now available on IMF TV. Get the latest information on myeloma and watch presentations from many of the top myeloma experts, including a welcome and overview from IMF President Susie Novis and an explanation of “Myeloma 101” from IMF Chairman Dr. Brian Durie. To watch the replay, please click HERE.

x

 Join the IMF's 9th Annual Comedy Celebration and Support Myeloma Research

The IMF 9th Annual Comedy Celebration is fast approaching! This year's gala is being headlined by actor and comedian Kevin Nealon and Late Show Band Leader Paul Shaffer will be leading the music portion of the evening. Proceeds will benefit the Peter Boyle Research Fund, as well as support the Black Swan Research Initiative, the IMF's groundbreaking and collaborative project aimed at developing the first definitive cure for myeloma. The gala event will kick off at 6 pm, Saturday, October 10 at the Wilshire Ebell Theatre & Club in Los Angeles. You can purchase tickets HERE.

 

x

 

 


Join Our Mailing List

 
12650 Riverside Drive, Suite 206 | North Hollywood, CA 91607-3421
IMF Hotline: 800-452-2873 or 818-487-7455
Privacy Policy | Unsubscribe
www.myeloma.org

.


 related articles